Several radiosensitizers have been clinically studied in a variety of malignancies, including CHK1/CHK2 inhibitors, ATM/ATR inhibitors, and PARP inhibitors, but clinical trials of pancreatic cancer-related radiosensitizers are still relatively scarce and most are in the preclinical stage. The gene discussed is PARP1; the disease is pancreatic neoplasm.